ADPT
Adaptive Biotechnologies Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow -8.3% ·
net new positions -9.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 18.90K | $493,205 | n/a | −1 |
| Q2 2026 | 106 | 0 | 115.12M | $2.47B | +6 | −7 |
| Q1 2026 | 110 | +7 | 111.61M | $1.55B | +11 | −4 |
| Q4 2025 | 102 | 0 | 114.72M | $1.86B | +1 | −1 |
| Q3 2025 | 21 | +2 | 74.70M | $1.12B | +2 | n/a |
| Q2 2025 | 16 | +2 | 70.34M | $819.50M | +2 | n/a |
| Q1 2025 | 11 | 0 | 46.91M | $348.49M | +2 | −2 |
| Q4 2024 | 11 | -1 | 53.01M | $317.80M | n/a | −1 |
| Q3 2024 | 11 | +2 | 55.08M | $282.02M | +2 | n/a |
| Q2 2024 | 9 | n/a | 54.39M | $196.88M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 29.99M | 0.0% | $179.81M | 0.6% | Held | 3 | SEC ↗ |
| 2 | ARK Investment Management ✦ | 9.42M | -18.8% | $56.50M | 0.5% | ▼ Trim | 3 | SEC ↗ |
| 3 | Millennium Management ✦ | 6.29M | -33.1% | $37.72M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 2.73M | n/a | $16.37M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.68M | +0.8% | $16.10M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 937.33K | +89.2% | $5.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 229.78K | +35.6% | $1.38M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 226.98K | +8.4% | $1.36M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 212.83K | -18.8% | $1.28M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 183.84K | +251.1% | $1.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 93.89K | -41.2% | $563,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| PRIMECAP Management | $389,274 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 295 holders, 151.59M shares, $2.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 300 sh · $7,635
Officer · 11.58K sh · $280,376
Officer · 11.88K sh · $304,272
Officer · 5.10K sh · $131,682
Officer · 6.78K sh · $173,390
Officer · 11.88K sh · $302,966
Officer · 9.18K sh · $232,738
Officer · 2.70K sh · $70,389
Officer · 11.88K sh · $313,777
Officer · 11.88K sh · $304,866
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology